Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies

被引：8

作者：

Zhu, Ni ^{[1
]}

Xiao, Haowen ^{[1
,2
]}

Wang, Li-Mengmeng ^{[1
]}

Fu, Shan ^{[1
]}

Zhao, Chan ^{[3
]}

Huang, He ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou 310003, Zhejiang, Peoples R China

[2] Guangzhou Liuhuaqiao Hosp, Dept Haematol, Guangzhou, Guangdong, Peoples R China

[3] Jinhua Cent Hosp, Dept Paediat, Jinhua, Zhejiang, Peoples R China

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 04期

基金：

中国国家自然科学基金; 国家高技术研究发展计划(863计划);

关键词：

genetic alterations; hematologic malignancies; protein tyrosine kinases; protein tyrosine phosphatases; target therapy; ACUTE MYELOID-LEUKEMIA; FACTOR RECEPTOR-BETA; CHRONIC MYELOMONOCYTIC LEUKEMIA; INTERNAL TANDEM DUPLICATION; ACUTE MYELOGENOUS LEUKEMIA; CELL MYELOPROLIFERATIVE DISORDER; RISK MYELODYSPLASTIC SYNDROME; ACUTE LYMPHOBLASTIC-LEUKEMIA; FIP1L1-PDGFRA FUSION GENE; SOMATIC PTPN11 MUTATIONS;

D O I：

10.2217/fon.14.280

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Protein tyrosine kinases and protein tyrosine phosphatases play pivotal roles in regulation of cellular phosphorylation and signal transduction with opposite functions. Accumulating evidences have uncovered the relevance of genetic alterations in these two family members to hematologic malignancies. This review underlines progress in understanding the pathogenesis of these genetic alterations including mutations and aberrant expression and the evolving protein tyrosine kinases and protein tyrosine phosphatases targeted therapeutic strategies in hematologic neoplasms.

引用

页码：659 / 673

页数：15

共 147 条

[61] Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia [J].

Inaba, Hiroto ;

Rubnitz, Jeffrey E. ;

Coustan-Smith, Elaine ;

Li, Lie ;

Furmanski, Brian D. ;

Mascara, Gerard P. ;

Heym, Kenneth M. ;

Christensen, Robbin ;

Onciu, Mihaela ;

Shurtleff, Sheila A. ;

Pounds, Stanley B. ;

Pui, Ching-Hon ;

Ribeiro, Raul C. ;

Campana, Dario ;

Baker, Sharyn D. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) :3293-3300

[62] Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation [J].

Jang, Seung Hun .

TUBERCULOSIS AND RESPIRATORY DISEASES, 2014, 76 (01) :8-14

[63]

JANSSEN JWG, 1991, ONCOGENE, V6, P2113

[64] Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL [J].

Kantarjian, Hagop ;

Giles, Francis ;

Wunderle, Lydia ;

Bhalla, Kapil ;

O'Brien, Susan ;

Wassmann, Barbara ;

Tanaka, Chiaki ;

Manley, Paul ;

Rae, Patricia ;

Mietlowski, William ;

Bochinski, Kathy ;

Hochhaus, Andreas ;

Griffin, James D. ;

Hoelzer, Dieter ;

Albitar, Maher ;

Dugan, Margaret ;

Cortes, Jorge ;

Alland, Leila ;

Ottmann, Oliver G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2542-2551

[65] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [J].

Kantarjian, Hagop ;

Shah, Neil P. ;

Hochhaus, Andreas ;

Cortes, Jorge ;

Shah, Sandip ;

Ayala, Manuel ;

Moiraghi, Beatriz ;

Shen, Zhixiang ;

Mayer, Jiri ;

Pasquini, Ricardo ;

Nakamae, Hirohisa ;

Huguet, Francoise ;

Boque, Concepcion ;

Chuah, Charles ;

Bleickardt, Eric ;

Bradley-Garelik, M. Brigid ;

Zhu, Chao ;

Szatrowski, Ted ;

Shapiro, David ;

Baccarani, Michele .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) :2260-2270

[66] Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure [J].

Khoury, H. Jean ;

Cortes, Jorge E. ;

Kantarjian, Hagop M. ;

Gambacorti-Passerini, Carlo ;

Baccarani, Michele ;

Kim, Dong-Wook ;

Zaritskey, Andrey ;

Countouriotis, Athena ;

Besson, Nadine ;

Leip, Eric ;

Kelly, Virginia ;

Bruemmendorf, Tim H. .

BLOOD, 2012, 119 (15) :3403-3412

[67] Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: Combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1 [J].

Kim, SC ;

Hahn, JS ;

Min, YH ;

Yoo, NC ;

Ko, YW ;

Lee, WJ .

BLOOD, 1999, 93 (11) :3893-3899

[68] Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia [J].

Kleppe, Maria ;

Lahortiga, Idoya ;

El Chaar, Tiama ;

De Keersmaecker, Kim ;

Mentens, Nicole ;

Graux, Carlos ;

Van Roosbroeck, Katrien ;

Ferrando, Adolfo A. ;

Langerak, Anton W. ;

Meijerink, Jules P. P. ;

Sigaux, Francois ;

Haferlach, Torsten ;

Wlodarska, Iwona ;

Vandenberghe, Peter ;

Soulier, Jean ;

Cools, Jan .

NATURE GENETICS, 2010, 42 (06) :530-U84

[69] A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy [J].

Knapper, Steven ;

Burnett, Alan K. ;

Littlewood, Tim ;

Kell, W. Jonathan ;

Agrawal, Sam ;

Chopra, Raj ;

Clark, Richard ;

Levis, Mark J. ;

Small, Donald .

BLOOD, 2006, 108 (10) :3262-3270

[70] The clinical development of FLT3 inhibitors in acute myeloid leukemia [J].

Knapper, Steven .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (10) :1377-1395

← 2 3 4 5 6 7 8 9 10 11 →